At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Novel Worksite Smoking Cessation Intervention for Hispanic Construction Workers
In Brief
A Phase 4 clinical trial evaluating Nicorette Gum, Nicoderm CQ, and 2 other interventions for Smoking Cessation. Completed, enrolled 134 participants across 1 site.
Detailed Summary
Construction workers have the highest rate of smoking among all occupations, and are frequently exposed to a wide range of workplace hazards (e.g. toxins), which interact with smoking to increase their health risks. Minority construction workers, in particular, have higher smoking and lower cessation rates compared to other groups, and they generally show lower access and participation in cessation and health promotion services. The number of Hispanic workers employed in the construction industry in the US has tripled in the past decade to 2.6 million (23% of all construction workers). This study will develop, administer, and evaluate a novel smoking cessation program in a hard-to-reach and underserved population of Hispanic male construction workers using using pilot cluster randomized clinical trial (RCT) to test the developed intervention for feasibility and potential efficacy.
Study Details
Timeline
Interventions
GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
Fax referral to the State smoking Quitline
One time face-to-face smoking cessation counseling and follow-up phone call